News und Analysen

Shares of the pharmaceutical giant Pfizer (NYSE: PFE) have suffered over the last three years, falling some 50% since December 2022. Shares have been weighed down by the collapse in revenue from its

While few investors have successfully timed the markets, buy-and-hold strategies tend to yield favorable results over the long term. The key is to select well-run companies that make highly

Abbott Laboratories (NYSE: ABT), a medical device specialist, has a lot going its way. The company has a large and diversified portfolio of products, which it routinely expands through new launches

Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on

Want some quality income-generating investments you can put in your portfolio for the long term, and not worry about? The stocks listed below check off those boxes and can make for ideal investments

CVS Health (NYSE: CVS) has been a huge outperformer this year. The stock is up about 79% so far in 2025 -- move than five times the return of the Health Care Select Sector SPDR Fund as well as the

Novo Nordisk (NYSE: NVO), a Denmark-based drugmaker, is currently a leader in the rapidly growing weight loss market. The company's Wegovy has practically become a household name, and it has plenty

A lot can change in five years. Take Vertex Pharmaceuticals (NASDAQ: VRTX), for example. In late 2020, the big biotech company's approved products focused on one indication – cystic fibrosis (CF)

Billionaire David Tepper's Appaloosa hedge fund has 45 holdings. That's large enough to be diversified. However, it's still small enough that it matters significantly which individual stocks and

The words "Ozempic" and "Wegovy" almost have become household names as these products have changed the lives of many – from our own friends and family to celebrities. These drugs, prescribed for

You may have noticed that the markets are exceptionally volatile at the moment. That's true whether we're talking about stocks, cryptocurrencies, or commodities.

During turbulent times, many

This year hasn't been the easiest for UnitedHealth Group (NYSE: UNH). The biggest U.S. health insurer has faced several challenges, from the unexpected departure of its chief executive officer back

Health insurer Centene (NYSE: CNC) is helping lead the stock market higher this morning, rising 8% through 11:05 a.m. on positive healthcare news out of Washington, D.C.:

It looks like Obamacare

After climbing 2.3% in October, the S&P 500 has taken a U-turn and driven steadily lower over the past few weeks. From the start of November through Nov. 21, the index has dipped about 3.5%.

But

Carnival (NYSE: CCL) has drawn investor interest for many reasons. Travel stocks remain popular, and the company's market lead in the cruise line industry and the continued strength in bookings

The past five years have been a roller-coaster ride for Pfizer (NYSE: PFE). The pharmaceutical giant shook up its business -- for instance, by getting rid of its off-patent drug unit -- and made a

Do you want to swing for the fences with a promising growth stock to buy and hold? While many growth stocks may seem overpriced these days, you can find some decently priced mid-cap stocks, whose

Shares of Exact Sciences (NASDAQ: EXAS) climbed on Thursday after the medical diagnostics specialist agreed to be acquired by Abbott (NYSE: ABT) for $21 billion.

As of 2:30 p.m. EST, Exact

On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48

Healthcare giant Pfizer (NYSE: PFE) has been offering a high yield for some time. But that hasn't been enough to get investors to buy up the stock. You can see that in its sluggish share price, and

Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24%

Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle

Heights Capital Management recently established a new position in ImmunityBio (NASDAQ:IBRX), buying 6,565,709 shares valued at approximately $16.15 million.

Heights Capital Management disclosed a

On November 14, 2025, 5AM Venture Management, LLC, disclosed that it sold out its Viking Therapeutics stake, a move representing an estimated $5.02 million net position change.

According to a